Heparan sulfate dissociates serum amyloid A (SAA) from acute-phase high-density lipoprotein, promoting SAA aggregation.
about
Historical and Current Concepts of Fibrillogenesis and In vivo Amyloidogenesis: Implications of Amyloid Tissue TargetingPathophysiology of heparan sulphate: many diseases, few drugsStructural mechanism of serum amyloid A-mediated inflammatory amyloidosisEndogenous Acute Phase Serum Amyloid A Lacks Pro-Inflammatory Activity, Contrasting the Two Recombinant Variants That Activate Human Neutrophils through Different ReceptorsDivergent effect of glycosaminoglycans on the in vitro aggregation of serum amyloid ANoncerebral Amyloidoses: Aspects on Seeding, Cross-Seeding, and Transmission.Proteomic analysis of highly prevalent amyloid A amyloidosis endemic to endangered island foxesCharacterization of the oligomerization and aggregation of human Serum Amyloid AStructure of serum amyloid A suggests a mechanism for selective lipoprotein binding and functions: SAA as a hub in macromolecular interaction networks.Targeting heparin and heparan sulfate protein interactions.Molecular crowding impacts the structure of apolipoprotein A-I with potential implications on in vivo metabolism and function.Serum Amyloid A3 is a High-Density Lipoprotein-associated Acute Phase Protein.Carbamylation of the amino-terminal residue (Gly1) of mouse serum amyloid A promotes amyloid formation in a cell culture model.Deposition, Clearance, and Reinduction of Amyloid A Amyloid in Interleukin 1 Receptor Antagonist Knockout Mice.Human SAA1-derived amyloid deposition in cell culture: a consistent model utilizing human peripheral blood mononuclear cells and serum-free medium.
P2860
Q26744469-B6B9B746-30AC-440C-8BAE-BD60BF3A7169Q26823840-88DDBDAD-C535-44F6-BA11-F38D8292B87DQ27683023-3FA275D1-6BDC-4732-94BF-EA772302E8E9Q28289800-9457D7F4-AC42-4A0D-BE8B-DE244A3B0E16Q33993673-2B682052-D087-42B1-BB4C-5314E797E478Q34549794-9EBCCE6F-BBF8-48B6-9589-C01B72F4F461Q34579925-D98DA76B-0A08-4DDF-B01C-BAE8EC2C4FB8Q34764150-76031BBE-DE5A-4420-A86A-7263A8E50785Q36723137-3444EA80-8717-4DF5-A0F6-EA1D7C756DFEQ39399937-E18F0EDD-6241-48D0-A6BD-07C64900F7BEQ39815577-72434842-B9DE-4271-8708-E1C882252A11Q47287451-F8699355-BDF4-423C-BD06-DE121A35D8BCQ51351788-76CBA51F-0768-49C6-A116-F3E2C7DD454EQ51548302-F1D5E43E-12E4-4DF9-96E3-5A7E7E94DC11Q54269926-1CDFD242-45A2-4A04-B092-4EE4A74D65C6
P2860
Heparan sulfate dissociates serum amyloid A (SAA) from acute-phase high-density lipoprotein, promoting SAA aggregation.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Heparan sulfate dissociates se ...... in, promoting SAA aggregation.
@en
Heparan sulfate dissociates se ...... in, promoting SAA aggregation.
@nl
type
label
Heparan sulfate dissociates se ...... in, promoting SAA aggregation.
@en
Heparan sulfate dissociates se ...... in, promoting SAA aggregation.
@nl
prefLabel
Heparan sulfate dissociates se ...... in, promoting SAA aggregation.
@en
Heparan sulfate dissociates se ...... in, promoting SAA aggregation.
@nl
P2093
P2860
P356
P1476
Heparan sulfate dissociates se ...... in, promoting SAA aggregation.
@en
P2093
Fredrik Noborn
Jin-Ping Li
John B Ancsin
Robert Kisilevsky
Wimal Ubhayasekera
P2860
P304
25669-25677
P356
10.1074/JBC.M112.363895
P407
P577
2012-05-31T00:00:00Z